D
Denovo Biopharma
A privately held biotech company providing a novel biomarker solution to personalize drug development
About Denovo Biopharma
Denovo Biopharma is a privately held biotech company specializing in personalized medicine through innovative biomarker solutions. Operating in the pharmaceutical and biotechnology sectors, Denovo Biopharma serves biotech and pharmaceutical companies by providing a unique platform for de novo genomic biomarker discovery. This technology is particularly valuable for late-stage clinical drugs that have shown unsatisfactory efficacy in trials. By identifying biomarkers that correlate with patient responsiveness to drug candidates, Denovo Biopharma enables more targeted and cost-effective clinical trials. The company's core technology uses archived clinical samples to discover biomarkers retrospectively, which can be applied across various therapeutic areas including oncology, metabolic disorders, cardiology, immunology, and neurology. Denovo Biopharma generates revenue by partnering with biotech and pharmaceutical companies to enhance their drug development processes, thereby increasing the likelihood of successful clinical outcomes.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GRANTOther financing | May 2024 | $12M | — | California Institute for Regenerative Medicine | ↗ |
| SERIES DOther financing | Dec 2020 | $46M | $415M | CICC · Sangel Capital · Zhejiang Paradise Silicon Valley Asset Management Group · China Resources Pharmaceutical Group Limited | — |
Growth signals
Latest recorded traffic for Denovo Biopharma is 580 monthly website visits, down 42% over the last three months. Denovo Biopharma's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Denovo Biopharma in the San Diego ecosystem
The Denovo Biopharma office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
California Institute for Regenerative Medicine
Series B and later7 investors entered at this stage
CICC
Yingke Capital
Sangel CapitalZhejiang Paradise Silicon Valley Asset Management Group
China Resources Pharmaceutical Group Limited
Fang Fund Partners- HBHosenCare Brothers
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Denovo Biopharma on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Denovo Biopharma’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









